However, considering that GIP acts glucagonotropically in patients with type 2 diabetes [21,109] the GIP component of dual incretin receptor agonists might counteract GLP-1-mediated inhibition of glucagon secretion, leading to a neutral effect on glucagon levels. This evidence concerns the gene GIP and type 2 diabetes mellitus.